Cipher Pharmaceuticals Inc (CPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPH) has a cash flow conversion efficiency ratio of 0.022x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$2.98 Million ≈ $2.15 Million USD) by net assets (CA$137.03 Million ≈ $99.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Cipher Pharmaceuticals Inc worth for the company's overall valuation and market capitalisation.
Cipher Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Cipher Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cipher Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cipher Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore how high is Cipher Pharmaceuticals Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pure Cycle Corporation
NASDAQ:PCYO
|
-0.028x |
|
Aju IB Investment Co. Ltd
KQ:027360
|
0.013x |
|
Soulpower Acquisition Corporation
NYSE:SOUL
|
-0.005x |
|
Ashtead Group PLC
LSE:AHT
|
0.208x |
|
Lightbridge Corporation
F:N7ON
|
-0.022x |
|
Eugene Inv&Sec
KO:001200
|
-0.013x |
|
Galata Wind Enerji Anonim Sirket
IS:GWIND
|
0.029x |
|
Unitech Computer Co Ltd
TW:2414
|
-1.105x |
Annual Cash Flow Conversion Efficiency for Cipher Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cipher Pharmaceuticals Inc from 2004 to 2025. View Cipher Pharmaceuticals Inc (CPH) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$126.01 Million ≈ $91.16 Million |
CA$30.25 Million ≈ $21.88 Million |
0.240x | +25.68% |
| 2024-12-31 | CA$102.34 Million ≈ $74.03 Million |
CA$19.55 Million ≈ $14.14 Million |
0.191x | -3.88% |
| 2023-12-31 | CA$80.52 Million ≈ $58.25 Million |
CA$16.00 Million ≈ $11.57 Million |
0.199x | +20.40% |
| 2022-12-31 | CA$64.08 Million ≈ $46.35 Million |
CA$10.57 Million ≈ $7.65 Million |
0.165x | -53.53% |
| 2021-12-31 | CA$38.90 Million ≈ $28.14 Million |
CA$13.81 Million ≈ $9.99 Million |
0.355x | -0.84% |
| 2020-12-31 | CA$32.64 Million ≈ $23.61 Million |
CA$11.69 Million ≈ $8.46 Million |
0.358x | +13.23% |
| 2019-12-31 | CA$28.01 Million ≈ $20.26 Million |
CA$8.86 Million ≈ $6.41 Million |
0.316x | -30.60% |
| 2018-12-31 | CA$24.76 Million ≈ $17.91 Million |
CA$11.28 Million ≈ $8.16 Million |
0.456x | -47.55% |
| 2017-12-31 | CA$22.94 Million ≈ $16.59 Million |
CA$19.93 Million ≈ $14.42 Million |
0.869x | +36.48% |
| 2016-12-31 | CA$18.01 Million ≈ $13.03 Million |
CA$11.47 Million ≈ $8.30 Million |
0.637x | +344.92% |
| 2015-12-31 | CA$54.26 Million ≈ $39.25 Million |
CA$7.76 Million ≈ $5.62 Million |
0.143x | +137.44% |
| 2014-12-31 | CA$6.62 Million ≈ $4.79 Million |
CA$-2.53 Million ≈ $-1.83 Million |
-0.382x | -298.20% |
| 2013-12-31 | CA$36.40 Million ≈ $26.33 Million |
CA$7.02 Million ≈ $5.08 Million |
0.193x | -65.14% |
| 2012-12-31 | CA$12.47 Million ≈ $9.02 Million |
CA$6.90 Million ≈ $4.99 Million |
0.553x | +744.04% |
| 2011-12-31 | CA$9.30 Million ≈ $6.73 Million |
CA$-799.22K ≈ $-578.14K |
-0.086x | -179.29% |
| 2010-12-31 | CA$11.47 Million ≈ $8.30 Million |
CA$1.24 Million ≈ $899.02K |
0.108x | +187.56% |
| 2009-12-31 | CA$10.47 Million ≈ $7.58 Million |
CA$-1.30 Million ≈ $-937.48K |
-0.124x | -50.64% |
| 2008-12-31 | CA$10.71 Million ≈ $7.74 Million |
CA$-879.21K ≈ $-636.01K |
-0.082x | +67.46% |
| 2007-12-31 | CA$15.83 Million ≈ $11.45 Million |
CA$-4.00 Million ≈ $-2.89 Million |
-0.252x | +58.75% |
| 2006-12-31 | CA$18.41 Million ≈ $13.32 Million |
CA$-11.27 Million ≈ $-8.15 Million |
-0.612x | +2.30% |
| 2005-12-31 | CA$19.16 Million ≈ $13.86 Million |
CA$-12.00 Million ≈ $-8.68 Million |
-0.626x | +2.30% |
| 2004-12-31 | CA$25.36 Million ≈ $18.34 Million |
CA$-16.26 Million ≈ $-11.76 Million |
-0.641x | -- |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more